NL-OMON20231已完成不适用
Part A: Clinical Study Protocol SC12: Safety of a single dose of 5 mg of hLF1-11 given to autologous haematopoietic stem cell transplant recipients.
AM-Pharma B.VRumpsterweg 6 3981 AK Bunnik Tel +31 (0) 30 228 92 22 Fax +31 (0) 30 228 92 200 个研究点目标入组 8 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 8
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Admitted for an autologous HSCT after myeloablative therapy with high-dose melfalan;
- •2. Managed with a 4-lumen central venous catheter;
排除标准
- •1. A history of, or presence of, significant respiratory, cardiovascular, neurological, haematological, endocrine, gastro intestinal, hepatic or renal disease or other condition known to interfere with the absorption, distribution, metabolism or excretion of drugs (as judged clinically relevant by the investigator);
- •2. Participation in a study with a new chemical entity or new molecular entity 3 months before or participation in a study with a registered drug less than 5 times of the half life of the registered drug before entering the study;
研究者
相似试验
已完成
1 期
Influenza A (H7N9) Vaccine Delivered Intradermally by High-density Microarray Patch (HD-MAP)H7N9 InfluenzaNCT06417853Vaxxas Pty Ltd267
已完成
2 期
Safety, Tolerability, and Efficacy of 12-weeks of Sovaprevir, ACH-3102, and Ribavirin in Treatment-naive GT-1 HCV ParticipantsHepatitis C, ChronicNCT01849562Alexion Pharmaceuticals, Inc.30
终止
1 期
A Study to Evaluate Escalating Doses of ASP1235 (AGS62P1) Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML)Acute Myeloid LeukemiaNCT02864290Astellas Pharma Global Development, Inc.43
已完成
1 期
Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in AdultsCOVID-19 VaccineNCT04546841University Hospital Tuebingen36
已完成
1 期
Study to Evaluate the Safety, Pharmacokinetics, Tissue Distribution, Metabolism and Dosimetry of Two Prostate Cancer Imaging AgentsProstate CancerNCT00712829Molecular Insight Pharmaceuticals, Inc.12